Standard BioTools Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Standard BioTools Inc. (LAB) reported Cash and Cash Equivalents, Period Increase (Decrease) of $37.34 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-18
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $59.57M.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$3.60M, a 116.84% decline year-over-year.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$2.55M.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$16.08M, a 277.68% decline year-over-year.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $37.34M, a 62.29% increase from fiscal 2017.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $23.01M, a 288.17% increase from fiscal 2016.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $5.93M.
- Standard BioTools Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$4.60M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $59.57M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $55.98M derived: sum of 2 quarters · filed 2019-03-18 | $53.43M derived: sum of 3 quarters · filed 2019-03-18 | $37.34M 10-K · filed 2019-03-18 |
| 2018-09-30 | -$3.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$6.14M derived: sum of 2 quarters · filed 2018-11-06 | -$22.23M 10-Q · filed 2018-11-06 | -$25.11M derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-06-30 | -$2.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | -$18.63M 10-Q · filed 2018-08-08 | -$21.52M derived: sum of 3 quarters · filed 2019-03-18 | -$173.00K derived: sum of 4 quarters · filed 2019-03-18 |
| 2018-03-31 | -$16.08M 10-Q · filed 2018-05-08 | -$18.97M derived: sum of 2 quarters · filed 2019-03-18 | $2.38M derived: sum of 3 quarters · filed 2019-03-18 | -$2.13M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $18.46M derived: sum of 2 quarters · filed 2019-03-18 | $13.96M derived: sum of 3 quarters · filed 2019-03-18 | $23.01M 10-K · filed 2019-03-18 |
| 2017-09-30 | $21.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $16.85M derived: sum of 2 quarters · filed 2018-11-06 | $25.90M 10-Q · filed 2018-11-06 | $28.64M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | -$4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $4.55M 10-Q · filed 2018-08-08 | $7.29M derived: sum of 3 quarters · filed 2019-03-18 | $3.70M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | $9.05M 10-Q · filed 2018-05-08 | $11.79M derived: sum of 2 quarters · filed 2019-03-18 | $8.20M derived: sum of 3 quarters · filed 2019-03-18 | $1.24M derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$853.00K derived: sum of 2 quarters · filed 2019-03-18 | -$7.81M derived: sum of 3 quarters · filed 2019-03-18 | $5.93M 10-K · filed 2019-03-18 |
| 2016-09-30 | -$3.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$10.55M derived: sum of 2 quarters · filed 2017-11-07 | $3.19M 10-Q · filed 2017-11-07 | $3.49M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$6.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $6.78M 10-Q · filed 2017-08-08 | $7.08M derived: sum of 3 quarters · filed 2018-03-08 | $12.15M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $13.74M 10-Q · filed 2017-05-09 | $14.04M derived: sum of 2 quarters · filed 2018-03-08 | $19.11M derived: sum of 3 quarters · filed 2018-03-08 | $5.87M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $5.37M derived: sum of 2 quarters · filed 2018-03-08 | -$7.87M derived: sum of 3 quarters · filed 2018-03-08 | -$4.60M 10-K · filed 2018-03-08 |
| 2015-09-30 | $5.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$8.16M derived: sum of 2 quarters · filed 2016-11-09 | -$4.90M 10-Q · filed 2016-11-09 | -$2.12M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | -$13.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$9.97M 10-Q · filed 2016-08-09 | -$7.19M derived: sum of 3 quarters · filed 2017-03-03 | -$19.94M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-03-31 | $3.27M 10-Q · filed 2016-05-09 | $6.04M derived: sum of 2 quarters · filed 2017-03-03 | -$6.70M derived: sum of 3 quarters · filed 2017-03-03 | -$64.04M derived: sum of 4 quarters · filed 2017-03-03 |
| 2014-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-03 | -$9.97M derived: sum of 2 quarters · filed 2017-03-03 | -$67.31M derived: sum of 3 quarters · filed 2017-03-03 | -$1.55M 10-K · filed 2017-03-03 |
| 2014-09-30 | -$12.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$70.08M derived: sum of 2 quarters · filed 2015-11-09 | -$4.32M 10-Q · filed 2015-11-09 | $10.84M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$57.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $8.42M 10-Q · filed 2015-08-10 | $23.58M derived: sum of 3 quarters · filed 2016-02-29 | $11.39M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $65.76M 10-Q · filed 2015-05-11 | $80.92M derived: sum of 2 quarters · filed 2016-02-29 | $68.73M derived: sum of 3 quarters · filed 2016-02-29 | $39.21M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.97M derived: sum of 2 quarters · filed 2016-02-29 | -$26.55M derived: sum of 3 quarters · filed 2016-02-29 | -$23.39M 10-K · filed 2016-02-29 |
| 2013-09-30 | -$12.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$41.72M derived: sum of 2 quarters · filed 2014-11-06 | -$38.55M 10-Q · filed 2014-11-06 | -$45.91M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | -$29.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | -$26.36M 10-Q · filed 2014-08-04 | -$33.72M derived: sum of 3 quarters · filed 2015-02-26 | $22.44M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | $3.17M 10-Q · filed 2014-05-12 | -$4.20M derived: sum of 2 quarters · filed 2015-02-26 | $51.96M derived: sum of 3 quarters · filed 2015-02-26 | $53.32M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | -$7.36M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $48.80M derived: sum of 2 quarters · filed 2015-02-26 | $50.15M derived: sum of 3 quarters · filed 2015-02-26 | $45.10M 10-K · filed 2015-02-26 |
| 2012-09-30 | $56.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $57.52M derived: sum of 2 quarters · filed 2013-11-07 | $52.46M 10-Q · filed 2013-11-07 | $54.13M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | -$3.70M 10-Q · filed 2013-08-07 | -$2.03M derived: sum of 3 quarters · filed 2014-03-12 | -$275.00K derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-03-31 | -$5.06M 10-Q · filed 2013-05-09 | -$3.38M derived: sum of 2 quarters · filed 2014-03-12 | -$1.63M derived: sum of 3 quarters · filed 2014-03-12 | -$47.34M derived: sum of 4 quarters · filed 2014-03-12 |
| 2011-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-12 | $3.42M derived: sum of 2 quarters · filed 2014-03-12 | -$42.28M derived: sum of 3 quarters · filed 2014-03-12 | $7.83M 10-K · filed 2014-03-12 |
| 2011-09-30 | $1.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$43.95M derived: sum of 2 quarters · filed 2012-11-09 | $6.16M 10-Q · filed 2012-11-09 | $6.80M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | -$45.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-14 | $4.41M 10-Q · filed 2012-08-14 | $5.05M derived: sum of 3 quarters · filed 2013-03-12 | $2.06M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | $50.11M 10-Q · filed 2012-05-15 | $50.75M derived: sum of 2 quarters · filed 2013-03-12 | $47.76M derived: sum of 3 quarters · filed 2013-03-12 | |
| 2010-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$2.35M derived: sum of 2 quarters · filed 2013-03-12 | -$8.88M 10-K · filed 2013-03-12 | |
| 2010-09-30 | -$2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | -$9.52M 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | -$6.53M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | -$3.19M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |